Merus N.V. announced interim clinical data, as of a July 31, 2023 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) cancer presented by Principal Investigator, Dr. Alison Schram of Memorial Sloan Kettering Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2023. The reported data are from the phase 1/2 eNRGy trial and EAP which are assessing the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.04 USD | +0.24% | +13.14% | +63.78% |
Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
Mar. 28 | Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.78% | 2.64B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer